HSC transduction in situ by cellular delivery of integrating viral vectors

通过整合病毒载体的细胞递送进行 HSC 原位转导

基本信息

  • 批准号:
    8532025
  • 负责人:
  • 金额:
    $ 36.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-08-05 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Therapies involving the genetic modification of stem cells hold substantial promise for the treatment of blood- and immunesystem disorders. They also face daunting obstacles limiting their feasibility and efficiency, related in part to poor target cell access and compromised stem cell survival in culture. We have recently made a series of novel observations that demonstrate the prolonged intracellular retention of HIV-derived lentivector particles by hematopoietic "carrier" cells and their capacity for secondary transduction events. The release of intact particles in murine transplantation studies led to preferential particle dissemination to host hematopoietic organs. These findings reveal a unique therapeutic opportunity to combine particle capture and active carrier cell homing for the delivery of lentivector to the marrow microenvironment. We hypothesize that lentivector particle capture and release by hematopoietic "carrier" cells, when combined with established homing mechanisms, can be exploited and optimized for the genetic modification of bone marrow stem cells in situ. We will systematically test this hypothesis in three specific aims. In a murine transplantation model with a stem cell defect we will ascertain the ability of carrier cells to phenotypically correct long-lived stem cells by in situ particle delivery, evaluate the mechanism by which this occurs and determine the dissemination to other organs. We will test strategies based on carrier cell homing and host conditioning to improve carrier cell access to the microenvironment and the efficiency of particle delivery. Finally, using a combination of biochemical assays and live-cell imaging we will investigate particle trafficking within carrier cells as a means of understanding and manipulating the mechanisms responsible for vector particle retention and release. The proposed strategy is based on our laboratory's observations, and adapts the established cancer gene therapy paradigm of using cellular carriers to target tumor tissue for virus particle delivery. Successful systemic delivery of lentivector particles by autologous cellular carriers directly to bone marrow stem cells will help overcome current impediments to gene therapy for hematopoietic and immune disorders. Without improved access to tissues and target cells, the therapeutic potential of gene therapy remains largely unfulfilled. The proposed development of a novel cellular approach to the delivery of genetic payload is therefore critically important not only for the intended correction of genetic disorders of the blood and immune system, but also as a tool for post injury repair in regenerative medicine.
描述(由申请人提供):涉及干细胞遗传修饰的疗法对血液和免疫系统疾病的治疗有很大的希望。它们还面临着限制其可行性和效率的令人生畏的障碍,部分原因是靶细胞获取困难和干细胞在培养中的存活率受损。我们最近进行了一系列新的观察,证明了造血“载体”细胞对HIV衍生的慢病毒载体颗粒的细胞内滞留时间延长及其次级转导事件的能力。在小鼠移植研究中,完整颗粒的释放导致优先颗粒扩散到宿主造血器官。这些发现揭示了将联合收割机颗粒捕获和主动载体细胞归巢结合用于将慢病毒载体递送至骨髓微环境的独特治疗机会。我们假设,慢病毒载体颗粒的捕获和释放造血“载体”细胞,当与建立归巢机制相结合,可以利用和优化骨髓干细胞原位遗传修饰。我们将在三个具体目标中系统地检验这一假设。在具有干细胞缺陷的鼠移植模型中,我们将确定载体细胞通过原位颗粒递送来表型校正长寿命干细胞的能力,评估这种情况发生的机制并确定向其他器官的传播。我们将测试基于载体细胞归巢和宿主调节的策略,以改善载体细胞进入微环境和颗粒递送效率。最后,我们将结合生物化学检测和活细胞成像,研究载体细胞内的颗粒运输,作为理解和操纵载体颗粒保留和释放机制的一种手段。所提出的策略是基于我们实验室的观察结果,并适应了已建立的癌症基因治疗范例,即使用细胞载体靶向肿瘤组织进行病毒颗粒递送。通过自体细胞载体将慢病毒载体颗粒成功地全身递送到骨髓干细胞将有助于克服目前造血和免疫疾病基因治疗的障碍。如果不改善对组织和靶细胞的获取,基因治疗的治疗潜力在很大程度上仍未实现。因此,提出的开发一种新的细胞方法来递送遗传有效载荷不仅对于预期的血液和免疫系统遗传疾病的校正至关重要,而且作为再生医学中损伤后修复的工具也至关重要。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector.
  • DOI:
    10.1186/s13287-016-0431-z
  • 发表时间:
    2016-11-19
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    Chakkaramakkil Verghese S;Goloviznina NA;Kurre P
  • 通讯作者:
    Kurre P
S/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection.
S/MAR序列赋予了不选择的非整合慢病毒载体插图的长期有丝分裂稳定性。
  • DOI:
    10.1093/nar/gku082
  • 发表时间:
    2014-04
  • 期刊:
  • 影响因子:
    14.9
  • 作者:
    Verghese SC;Goloviznina NA;Skinner AM;Lipps HJ;Kurre P
  • 通讯作者:
    Kurre P
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter Kurre其他文献

Peter Kurre的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter Kurre', 18)}}的其他基金

Hematopoietic stem and progenitor cell regulation of the niche through extracellular vesicles
造血干细胞和祖细胞通过细胞外囊泡调节生态位
  • 批准号:
    10634681
  • 财政年份:
    2022
  • 资助金额:
    $ 36.65万
  • 项目类别:
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia
范可尼贫血中胎儿造血受限和克隆限制
  • 批准号:
    10591494
  • 财政年份:
    2020
  • 资助金额:
    $ 36.65万
  • 项目类别:
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia
范可尼贫血中胎儿造血受限和克隆限制
  • 批准号:
    10377337
  • 财政年份:
    2020
  • 资助金额:
    $ 36.65万
  • 项目类别:
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy
用于干细胞基因治疗的有丝分裂稳定的慢病毒附加体
  • 批准号:
    9348639
  • 财政年份:
    2015
  • 资助金额:
    $ 36.65万
  • 项目类别:
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy
用于干细胞基因治疗的有丝分裂稳定的慢病毒附加体
  • 批准号:
    9020642
  • 财政年份:
    2015
  • 资助金额:
    $ 36.65万
  • 项目类别:
HSC transduction in situ by cellular delivery of integrating viral vectors
通过整合病毒载体的细胞递送进行 HSC 原位转导
  • 批准号:
    7670405
  • 财政年份:
    2008
  • 资助金额:
    $ 36.65万
  • 项目类别:
HSC transduction in situ by cellular delivery of integrating viral vectors
通过整合病毒载体的细胞递送进行 HSC 原位转导
  • 批准号:
    7902251
  • 财政年份:
    2008
  • 资助金额:
    $ 36.65万
  • 项目类别:
HSC transduction in situ by cellular delivery of integrating viral vectors
通过整合病毒载体的细胞递送进行 HSC 原位转导
  • 批准号:
    8123344
  • 财政年份:
    2008
  • 资助金额:
    $ 36.65万
  • 项目类别:
HSC transduction in situ by cellular delivery of integrating viral vectors
通过整合病毒载体的细胞递送进行 HSC 原位转导
  • 批准号:
    8318345
  • 财政年份:
    2008
  • 资助金额:
    $ 36.65万
  • 项目类别:
Genetic targeting of proviral integration in stem cells
干细胞中原病毒整合的基因靶向
  • 批准号:
    7625013
  • 财政年份:
    2005
  • 资助金额:
    $ 36.65万
  • 项目类别:

相似海外基金

Phase I/II clinical trial of autologous T cell gene therapy to treat X-linked lymphoproliferative disease (XLP)
自体T细胞基因疗法治疗X连锁淋巴增殖性疾病(XLP)的I/II期临床试验
  • 批准号:
    MR/Y019458/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.65万
  • 项目类别:
    Research Grant
Fabrication and Evaluation of Poly(glycerol sebacate) based small diameter vascular graft as a potent substitution for autologous vessels
基于聚(甘油癸二酸酯)的小直径血管移植物作为自体血管有效替代品的制造和评估
  • 批准号:
    2897580
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
    Studentship
Autologous Bone Marrow Aspirate Concentrate for the Treatment of Osteonecrosis of the Femoral Head
自体骨髓抽吸浓缩液治疗股骨头坏死
  • 批准号:
    10658324
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
Identifying multimodal biomarkers for autologous serum tears in the treatment of chronic postoperative ocular pain
识别治疗慢性术后眼痛的自体血清泪液的多模式生物标志物
  • 批准号:
    10794761
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
SBIR Phase II: An Injectable Protein Matrix to Enhance the Stability of Autologous Fat Grafts
SBIR II 期:可注射蛋白质基质,增强自体脂肪移植物的稳定性
  • 批准号:
    2304430
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
    Cooperative Agreement
MICA: Strategy for heart repair in Duchenne Muscular Dystrophy (DMD) using genetically engineered autologous Mesoangioblasts
MICA:利用基因工程自体中成血管细胞修复杜氏肌营养不良症 (DMD) 的心脏的策略
  • 批准号:
    MR/X00466X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
    Fellowship
Application of Autologous Connective Tissue Sheets Created in Patients' Bodies to Pediatric Cardiac Valvuloplasty and Development of Dedicated Molds
患者体内自体结缔组织片在小儿心脏瓣膜成形术中的应用及专用模具的开发
  • 批准号:
    23K15543
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
SBIR 第二阶段,主题 429:自体和同种异体细胞治疗制造的新范式
  • 批准号:
    10976161
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia
计划对小唾液腺来源的自体 MSC 进行 I 期研究,以预防长期辐射引起的口干症
  • 批准号:
    10720234
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
  • 批准号:
    10721983
  • 财政年份:
    2023
  • 资助金额:
    $ 36.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了